Latest Mitochon Pharmaceuticals News & Updates

See the latest news and media coverage for Mitochon. We track all announcements, press releases, and industry mentions in real time, all in one place.

Mitochon Pharmaceuticals (Mitochon)

Clinical-stage biotech developing mitochondria-targeting drugs

mitochonpharma.com

Headquarters: Blue Bell, United States
Founded year: 2014
Company type: Private company
Number of employees: 4–10

Last updated Today

Latest news about Mitochon Pharmaceuticals (Mitochon)

In short: Mitochon Pharmaceuticals completed promising clinical trials for its lead drug MP101 and secured research grants for traumatic brain injuries.

Company announcements

April 30 Mitochon

Mitochon Pharmaceuticals repurposes DNP for brain treatments

MP101 and MP201 modulate mitochondria for neuroprotection, mimicking fasting benefits and inducing BDNF for cognition and neural growth.

February 24 Mitochon

Mitochon Pharmaceuticals completes promising ALS drug trial

Early-stage European study with 18 patients over two weeks shows signs of slowing disease progression by stabilizing mitochondria. One patient regained ability to button shirt.

January 1 Mitochon

Mitochon completes ALS studies with MP101

In 2025, they conducted two 14-day European studies showing remarkable CSF biomarkers. They plan a larger 2026 study on sporadic ALS. MP101 reversed paralysis in hSOD1 model.

18 November 2024 Mitochon

Mitochon Pharmaceuticals announces DNP preserves motor function in ALS mice

Micro-doses of DNP delayed disease onset, improved motor coordination, preserved muscle function, and induced functional recovery in hSOD1G93A mice.

Media coverage

May 18 The Manila Times

Nexentis Announces MitoCareX Bio Achieves Key R&D Milestone, Generating a Substantially Improved Hit Molecule on the Path to Pre-Clinical Development | The Manila Times

MITOLINE® - the U.S. ... in mitochondrial drug discovery: the near-total absence of experimentally solved 3D structures for this important protein class. The initial hit...

February 12 Technical.ly

ALS drug trial shows promising signs for Philly-area startup's once-daily pill

A Blue Bell startup is studying whether stabilizing mitochondria can slow progression in neurodegenerative disease.

Never miss news about Mitochon

Track Mitochon and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Mitochon competitors & trending companies

Browse news for competitors to Mitochon and other trending companies.